Pre-market Hot Trades in US Stocks
Dermata Therapeutics is down 7.01% in pre-market trading. Based on recent news,
<ol>
<li>
On December 30, Dermata Therapeutics issued a statement reminding investors of the inherent risks and uncertainties in drug development, approval, and commercialization processes. The announcement pointed out that past results of clinical trials may not represent future trial outcomes, leading to market concerns about the company's prospects and a decline in stock price.
</li>
<li>
On December 30, Dermata Therapeutics Chairman Gerald Proehl purchased 612,745 shares of the company at an average price of $2.04 per share. Although this news typically boosts market confidence, it failed to effectively offset the negative impact due to the risk warnings in the announcement.
</li>
<li>
On December 29, Dermata Therapeutics released a related announcement through the EDGAR system, further emphasizing the various risks and uncertainties faced by the company, increasing market anxiety. The drug development industry faces high risks and uncertainties.
</li>
</ol>
KLA is up 3.36% in pre-market trading. Based on recent news,
<ol>
<li>
On December 30, Cadence Design Systems was listed as the preferred choice in the electronic design automation field, but US-China trade tensions may pose risks. This news boosted market confidence in related tech stocks, driving KLA's stock price up.
</li>
<li>
On December 30, Bank of America reported that Analog Devices has high free cash flow, but an economic recession may impact its high-performance chip spending. Nevertheless, Bank of America remains optimistic about chip stocks, further enhancing market confidence in tech stocks.
</li>
<li>
On December 30, Bank of America held a constructive view on chip stocks for 2026, believing that the market underestimates the importance of large tech companies in capital expenditures. This perspective supports the overall upward trend of tech stocks. Tech stocks are performing strongly, and the market is optimistic about AI investment prospects.
</li>
</ol>
Top Gainers in Pre-market US Stocks
ChowChow Cloud is up 62.82% in pre-market trading, with no significant recent news. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Eason Tech is up 37.25% in pre-market trading, with no significant recent news. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Ironwood Pharmaceuticals is up 35.32% in pre-market trading. Based on recent key news:
<ol>
<li>
On January 2, Ironwood Pharmaceuticals announced that its revenue outlook for 2026 exceeds Wall Street expectations, primarily due to an anticipated increase in net sales of the gastrointestinal disease treatment drug Linzess, co-marketed with AbbVie. This news significantly boosted the stock price. Source: Business Wire
</li>
<li>
On January 2nd, the company expects adjusted EBITDA to exceed $300 million in 2026, a significant increase compared to last year. This financial outlook has strengthened market confidence in the company's future profitability. Source: SEC announcement
</li>
<li>
On January 2nd, Ironwood Pharmaceuticals announced a meeting with the FDA, planning to initiate a confirmatory trial for the treatment of short bowel syndrome in the first half of 2026. This move demonstrates the company's positive progress in R&amp;D, further boosting its stock price. Source: WSJ The pharmaceutical industry has great growth potential, with significant capital inflows
</li>
</ol>

DRMA

KLAC

Dermata Therapeutics pre-market down 7.01%; KLA pre-market up 3.36%; ChowChow Cloud pre-market up 62.82%; Eason Tech pre-market up 37.25%; Ironwood Pharmaceuticals pre-market up 35.32%

Pre-market hot trades in US stocks: Dermata Therapeutics pre-market down 7.01%; KLA pre-market up 3.36%